Aquilant and Mirai Medical Announce Strategic Partnership to Advance GI Cancer Treatment in the UK

Aquilant is excited to announce a new partnership with Mirai Medical to bring the innovative EndoVE system to gastrointestinal (GI) clinicians across the UK. This collaboration marks a significant step forward in the treatment of colorectal cancer, particularly for patients with inoperable disease. 

EndoVE, powered by Mirai’s proprietary ePORE® technology, delivers precise, non-thermal ablation via endoscopic pulsed electric fields. This approach targets tumours while preserving surrounding healthy tissue, offering a safe, fast, and effective solution for GI disease management. 

“We’re delighted to partner with Aquilant to bring our endoscopic pulsed electric field platform to GI clinicians across the UK,” said Declan Soden, CEO of Mirai Medical. “Together, we’re advancing gastrointestinal cancer treatment and improving outcomes for patients.” 

David Atkinson, Business Development Director at Healthcare 21, added: “Aquilant is delighted to partner with Mirai to promote the ground-breaking EndoVE technology. This collaboration represents a shared commitment to advancing patient care, particularly in enhancing palliative outcomes for those living with colorectal cancer. Together, we aim to bring innovative solutions that make a meaningful difference in patients’ lives.” 

Learn more about EndoVE here.